An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Incyte

Status and phase: Terminated; Phase 1

Conditions: Nasopharyngeal Cancer; Esophageal Cancer; Cholangiocarcinoma; Solid Tumors; Ovarian Cancer; Hepatocellular Carcinoma (HCC)

Treatments: Drug: INCB062079

Study type: Interventional

Funder types: Industry

Identifiers

NCT03144661

INCB 62079-101

2017-001153-13 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and tolerability, and determine the maximum tolerated dose of INCB062079 in subjects with advanced hepatocellular carcinoma and other malignancies.

Enrollment: 25 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Part 1: HCC; cholangiocarcinoma; or esophageal, nasopharyngeal, or serious ovarian cancer, regardless of FGF19/FGFR4 status; or other solid tumor malignancies with documented FGF19/FGFR4 alteration (FGF19/FGFR4 pathway activating alterations include, but are not limited to, FGFR4 amplification, FGFR4 activating mutations, and FGF19 amplification) based on local testing.

• Part 2: Subjects will be enrolled into 1 of 3 cohorts:

  • Cohort A: HCC with FGF19 amplification.
  • Cohort B: HCC without FGF19 amplification.
  • Cohort C: cholangiocarcinoma, esophageal, nasopharyngeal or serous ovarian cancers (regardless of FGF19/FGFR4 status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.

• Has progressed after prior therapy and either a) there is no further effective standard anticancer therapy available (including subject refusal) or b) is intolerant to standard anticancer therapy.

• Life expectancy > 12 weeks.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Part 1) or 0-2 (Part 2).

• Archival tumor specimen according to protocol-defined criteria.

• Centrally analyzed screening C4 (bile acid synthesis precursor) results must be below 40.9 ng/mL, which is the upper limit as determined by the sponsor.

• Must agree to take bile acid sequestrants while taking INCB062079.

Exclusion criteria

• Treatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications within 28 days before first dose of study drug; subjects must have recovered from AEs due to previously administered therapies.
• Prior receipt of a selective FGFR4 inhibitor within the last 6 months.
• Laboratory parameters outside the protocol-defined ranges.
• History or presence of an abnormal ECG that in the investigator's opinion is clinically meaningful.
• Prior radiotherapy within 2 weeks of study treatment. A 1-week washout period is permitted for palliative radiation to non- central nervous system (CNS) disease with medical monitor approval.
• History of human immunodeficiency virus infection.
• Untreated brain or CNS metastases or brain/CNS metastases that have progressed. Subjects with previously treated and clinically stable brain/CNS metastases and who are off all corticosteroids for ≥ 4 weeks are eligible.
• Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment, except concomitant antiviral systemic therapy for chronic hepatitis B or C.
• Child-Pugh liver function Class B or C.
• History of clinically significant or uncontrolled cardiac disease.
• History of allergic reactions to INCB062079, any of the excipients of INCB062079 or similar compounds.
• Pregnant or nursing women or subjects expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after last dose of study drug.
• Any medical condition that would in the investigator's judgment interfere with full participation in the study, including administration of study medication and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

25 participants in 8 patient groups

Part 1 - INCB062079 10mg QD

Experimental group

Description:

INCB062079 was administered at 10mg once daily

Treatment:

Drug: INCB062079

Part 1 - INCB062079 10mg BID

Experimental group

Description:

NCB062079 was administered at 10mg twice daily

Treatment:

Drug: INCB062079

Part 1 - INCB062079 15mg BID

Experimental group

Description:

NCB062079 was administered at 15mg twice daily

Treatment:

Drug: INCB062079

Part 1 - INCB062079 10 mg BID + BAS

Experimental group

Description:

NCB062079 was administered at 10 mg twice daily in combination with bile acid sequestrants (BAS)

Treatment:

Drug: INCB062079

Part 1 - INCB062079 15 mg BID + BAS

Experimental group

Description:

NCB062079 was administered at 15mg twice daily in combination with bile acid sequestrants (BAS)

Treatment:

Drug: INCB062079

Part 2 Dose Expansion - Cohort A

Experimental group

Description:

HCC Subjects with FGF19 amplification were enrolled to evaluate the dose selected in Part 1

Treatment:

Drug: INCB062079

Part 2 - Dose Expansion Cohort B

Experimental group

Description:

HCC Subjects without FGF19 amplification were enrolled to evaluate the dose selected in Part 1

Treatment:

Drug: INCB062079

Part 2 - Dose Expansion Cohort C

Experimental group

Description:

Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration were enrolled to evaluate the dose selected in Part 1

Treatment:

Drug: INCB062079